Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 3;15(1):68.
doi: 10.1186/s13011-020-00309-y.

Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway

Collaborators, Affiliations

Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway

Christer Frode Aas et al. Subst Abuse Treat Prev Policy. .

Abstract

Background: Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy (OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge on the health-related quality of life (HRQoL) of long-term patients in OAT. This study measures HRQoL and self-perceived health of long-term patients on OAT, compares the scores to a Norwegian reference population, and assesses changes in these scores at 1-year follow up.

Methods: We conducted a nested prospective cohort study among nine OAT outpatient clinics in Norway. 609 OAT patients were included, 245 (40%) followed-up one year later. Data on patient characteristics, HRQoL, and self-perceived health was collected. HRQoL was assessed with the EQ-5D-5L, which measures five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) on a five-point Likert scale (from "no problems" to "extreme problems"). An UK value set was applied to calculate index values (from 0 to 1) for the EQ-5D-5L and compare them to a Norwegian reference population. Self-perceived health was measured with EQ-VAS (from 0 to 100).

Results: Mean (standard deviation (SD)) EQ-5D-5L index value at baseline was 0.699 (0.250) and EQ-VAS 57 (22) compared to 0.848 (0.200) and 80(19) for the Norwegian reference population. There were large variations in EQ-5D-5L index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The lowest EQ-5D-5L index values were observed for female patients, age groups older than 40 years and for methadone users. At follow-up, improvements in HRQoL were observed across almost all dimensions and found significant for mobility and pain/discomfort. Mean (SD) overall index value and EQ-VAS at follow up were 0.729 (0.237) and 59 (22) respectively.

Conclusion: The average HRQoL and self-perceived health of OAT patients is significantly lower than that of the general population, and lower than what has been found among other severe somatic and psychiatric conditions. Around 34% had very good HRQoL, higher than average Norwegian values, and around 5% had extremely poor HRQoL.

Keywords: EQ-5D; Epidemiology; Health related quality of life; Opiate substitution therapy; Opioid agonist therapy; Opioid dependence; Quality of life.

PubMed Disclaimer

Conflict of interest statement

None of the authors have competing interests.

Figures

Fig. 1
Fig. 1
Proportion of individuals reporting problems by EQ-5D-5L domain; overall, by age, gender and OAT medication. OAT = opioid agonist therapy. Altogether 609 respondents, 8 patients missed values on one dimension. 11 patients, which did not receive either methadone or buprenorphine-based medications are left out of the illustration but not analysis. Proportions (%) and dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). 1A: Overall, 1B: Gender 1C: OAT medication 1D: Age groups
Fig. 2
Fig. 2
Pen’s Parade: distribution from lowest to greatest health. Pen’s Parade: The distribution in baseline EQ-5D-5L index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The dotted line represent the average reported index value of the Norwegian reference population
Fig. 3
Fig. 3
EQ-5D-5L domains at baseline versus follow-up. OAT = opioid agonist therapy. Proportions (%) and dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). Baseline and follow-up for the 245 patients who were eligible for follow-up analysis

References

    1. World Health Organization. Management of substance abuse: Dependence syndrome, ICD-10 Clinical description; 2020. https://www.who.int/substance_abuse/terminology/definition1/en/.
    1. Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018;16(1):69. - PMC - PubMed
    1. Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet (London, England) 2019;394(10208):1560–1579. - PMC - PubMed
    1. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217. - PMC - PubMed
    1. European Monitoring Centre for Drugs and Drug Addiction: European Drug Report. Trends and Developments. In.; 2019.

Publication types

MeSH terms

Substances